T he association between adiposity and hypertension has been well established in observational studies, 1-3 and intervention studies have also showed that weight loss can lower blood pressure (BP) in obese hypertensives. 4 In United States, the prevalence of hypertension in obese adults is 40.8%. 5 The comorbidities of adiposity and hypertension significantly increase the probability of adverse cardiovascular events and represent a serious health hazard nationwide. 6 Existing evidence suggests that the presence of these comorbidities varies widely in the obese population. A distinct subgroup of obese individuals, known as metabolically healthy obesity, is considered less prone to develop metabolic abnormalities than expected for their adiposity. 7, 8 Studies have demonstrated that the consistent metabolic characteristics of these metabolically healthy obese individuals was the preserved insulin sensitivity status. 9, 10 Insulin resistance or diminished insulin sensitivity, as a core feature of metabolic syndrome, is closely associated with obesity, hypertension, dyslipidemia, and hyperglycemia.
T he association between adiposity and hypertension has been well established in observational studies, [1] [2] [3] and intervention studies have also showed that weight loss can lower blood pressure (BP) in obese hypertensives. 4 In United States, the prevalence of hypertension in obese adults is 40.8%. 5 The comorbidities of adiposity and hypertension significantly increase the probability of adverse cardiovascular events and represent a serious health hazard nationwide. 6 Existing evidence suggests that the presence of these comorbidities varies widely in the obese population. A distinct subgroup of obese individuals, known as metabolically healthy obesity, is considered less prone to develop metabolic abnormalities than expected for their adiposity. 7, 8 Studies have demonstrated that the consistent metabolic characteristics of these metabolically healthy obese individuals was the preserved insulin sensitivity status. 9, 10 Insulin resistance or diminished insulin sensitivity, as a core feature of metabolic syndrome, is closely associated with obesity, hypertension, dyslipidemia, and hyperglycemia. 11 Although obese individuals are significantly more insulin resistant than their lean counterparts, 12 there are also 31.7% of obese adults (≈19.5 million people) being insulin sensitive. 13 It has been proposed that the association between obesity and metabolic disorders is more than merely a dose-response relationship. 7, 14, 15 Insulin resistance is considered a key link for the association of obesity with type 2 diabetes mellitus, hypertension, and cardiovascular disease. Furthermore, longitudinal studies have shown that insulin-sensitive obese individuals may have relatively lower risk of type 2 diabetes mellitus and cardiovascular disease. [16] [17] [18] [19] In addition, there is evidence showing that the presence of metabolic disorders varies widely among obese individuals as a function of differences in the degree of insulin sensitivity. 14, 20 Compensatory hyperinsulinemia seen in insulin resistance has been suggested to play a causal role in development of hypertension by activating sympathetic nervous system and causing sodium retention. 21, 22 However, some human and animal studies suggest that insulin resistance might not be directly involved in the pathogenesis of hypertension. 21, [23] [24] [25] [26] Despite extensive observations on insulin-resistant and sensitive obesity, it is not clear whether the role of adiposity in the development of hypertension is modified by insulin resistance. In this study, we aimed to assess the hypothesis that insulinsensitive obesity is associated with a relatively lower risk of hypertension than insulin-resistant obesity, and the adiposityhypertension association is modified by insulin resistance.
Materials and Methods

Study Cohort
The Bogalusa Heart Study is a series of long-term studies in a semirural biracial (65% white and 35% black) community in Bogalusa, Louisiana begun in 1973 by Dr Gerald Berenson, focusing on the early natural history of cardiovascular disease since childhood. 27 Ten cross-sectional surveys of adults aged 18 to 52 years who had been previously examined as children were conducted in Bogalusa, Louisiana between 1980 and 2010. Linking these repeated cross-sectional examinations conducted every 2 to 3 years has resulted in serial observations. The longitudinal cohort of this study consisted of 1624 middle-aged normotensive adults (1148 whites and 476 blacks, ages 18.0-43.5 years at baseline) enrolled in the Bogalusa Heart Study. These subjects were examined 2 times at baseline and follow-up for BMI, fasting glucose and insulin, and BP during adulthood, with an average follow-up period of 16.0 years (range, 5.0-31.2 years).
All subjects in this study gave informed consent at each examination. Study protocols were approved by the Institutional Review Board of the Tulane University Health Sciences Center.
General Examinations
Standardized protocols were used by trained examiners across all surveys since 1973. 27 Subjects were instructed to fast for 12 hours before screening. Replicate measurements of height and weight were made, and the mean values were used for analysis. Body mass index (BMI, weight in kilograms divided by the square of the height in meters) was used as a measure of overall adiposity. Waist circumference (WC) was measured midway between the lowest border of rib cage and the upper border of iliac crest while the child was standing. Information on smoking status was obtained by questionnaires. Those who smoked ≥1 cigarette per day during the past 12 months were considered current smokers.
BP levels were measured between 8:00 am and 10:00 am on the right arm of subjects in a relaxed, sitting position by 2 trained observers (3 replicates each). Systolic BP (SBP) and diastolic BP (DBP) were recorded using a mercury sphygmomanometer. The fifth Korotkoff phase was used for DBP. The mean values of the 6 readings were used for analysis. Hypertension was defined as SBP≥140 mm Hg or DBP≥90 mm Hg or taking antihypertensive medications at the time of survey.
A commercial radioimmunoassay kit was used for measuring plasma immunoreactive insulin levels (Phadebas; Pharmacia Diagnostics, Piscataway, NJ). Plasma glucose levels were measured as part of a multiple chemistry profile (SMA20; Laboratory Corporation of America, Burlington, NC) by a glucose oxidase method. Insulin resistance status was assessed using the homeostasis model assessment (HOMA) of insulin resistance according to the formula described previously: HOMA=insulin (µU/mL)×glucose (mmol/L)/22.5.
28
Statistical Methods
All statistical analyses were performed with SAS version 9.3 (SAS Institute, Cary, NC). Adiposity at baseline was defined as BMI≥25 and insulin resistance as HOMA>55th percentile, with 10% of baseline HOMA in the middle (46th-55th percentile) excluded to make groups more distinct. The remaining cohort was accordingly divided into 4 groups: group I (BMI↓/HOMA↓), group II (BMI↓/HOMA↑), group III (BMI↑/HOMA↓), and group IV (BMI↑/HOMA↑). The prevalence of incident hypertension at follow-up was compared between the baseline insulin-sensitive obese (group III, n=149) and insulinresistant obese groups (group IV, n=383). The 4 groups were also classified by low and high levels of baseline WC defined as below and above sex-specific 64th percentile of WC (86.6 cm for males and 76.3 cm for females), respectively, The reason for choosing this cutoff value was based on the prevalence (36%) of overweight/obesity (BMI≥25) in this study cohort of young adults at baseline. Analyses of covariance were performed using general linear models to test differences in study variables between race, sex, and adiposity groups. Multivariable logistic regression models were used to examine the association between adiposity groups and hypertension as dichotomous variables, adjusted for baseline age, race, sex, and follow-up years. The modification effect of insulin resistance on the association between BMI and hypertension (or levels of BP) was examined by multivariable logistic (or linear) regression interaction models using the entire sample. Because the wide range of follow-up time might have an impact on odds ratios (ORs) for the association between adiposity/insulin resistance and hypertension, logistic regression models were performed by tertile groups of follow-up years to test the heterogeneity of the association parameters among subgroups.
Results
Mean levels of study variables at baseline and follow-up by race and sex are summarized in Table 1 . Baseline BMI, WC, heart rate, and glucose showed significant race and sex differences except for race difference in glucose in females and heart rate in males; black females had significantly higher insulin and HOMA than white females. There were significant race differences in follow-up BMI, WC, glucose, insulin, and HOMA (blacks>whites) in females. Follow-up BP showed significant sex (males>females) and race differences (blacks>whites); follow-up heart rate had a significant sex difference (females>males). After a 16-year follow-up on average, 320 (19.7%) incident hypertension patients were observed, with prevalence of hypertension at follow-up being higher in blacks than in whites (31.0% versus 15.0%, P<0.001). After adjusting for age, race, and sex, baseline heart rate was significantly correlated with baseline insulin (r=0.053, P=0.034), baseline SBP (r=0.118, P<0.001), and baseline DBP (r=0.143, P<0.001). Baseline heart rate was significantly correlated with follow-up HOMA (r=0.087, P=0.001), follow-up DBP (r=0.059, P=0.017), marginally correlated with follow-up insulin (r=0.051, P=0.055), but not correlated with follow-up SBP (r=0.029, P=0.249), with additional adjustment for follow-up years. Baseline heart rate was not significantly correlated with BMI and WC at both baseline and follow-up. Figure 1 presents OR and 95% confidence interval of baseline BMI, WC, glucose, insulin, and HOMA for incident hypertension by race and in total sample, adjusted for age, sex, follow-up years, and race (for the total sample). Baseline BMI, WC, glucose, insulin (log transformed), and HOMA (log transformed) were significantly associated with incident hypertension at follow-up in the total sample. ORs did not differ significantly between blacks and whites. Table 2 shows mean levels of study variables in 4 groups classified according to levels of baseline BMI and HOMA, with 10% of baseline HOMA values around the median value excluded. The remaining cohort was divided into 4 groups as shown in Table 2 . Among overweight/obese individuals based on baseline BMI≥25, the insulin-resistant obese group (group IV) had significantly higher levels of BMI, glucose, insulin, HOMA, and BP at follow-up than the insulin-sensitive obese group (group III), adjusted for baseline age, race, sex, and follow-up years. Notably, the prevalence of incident hypertension at follow-up was significantly higher in the insulinresistant obese group than in the insulin-sensitive obese group (32.1% versus 22.1%, P<0.001). Table 3 shows the association between baseline insulinresistant adiposity (group IV) and hypertension at follow-up, using insulin-sensitive adiposity (group III) as a reference. Individuals with baseline insulin-resistant adiposity were 1.9 times (P=0.008) more likely to have hypertension than those with baseline insulin-sensitive adiposity, after adjustment for baseline age, race, sex, smoking, and follow-up years. The ORs did not differ significantly between whites (OR, 2.50; P=0.008) and blacks (OR, 1.41; P=0.335), with P=0.238 for race difference in ORs. Because the follow-up period of study subjects ranged from 5.0 to 31.2 years, logistic regression models were performed by tertile groups of follow-up years to test the heterogeneity of ORs among 3 subgroups. The follow-up year range was 5.0 to 11.7 years in tertile I, 11. As shown in Figure 3 , slopes of increasing follow-up BP levels with increasing baseline BMI, measured as regression coefficients (β), were significantly greater in the insulin-resistant group than in the insulin-sensitive group (β=0.74 versus β=0.35 for SBP, P=0.004 for difference in slopes; β=0.51 versus β=0.23 for DBP, P=0.001 for difference in slopes).
Insulin-sensitive adiposity and insulin-resistant adiposity groups were also classified according to levels of baseline Continuous variables are presented as mean (SD). BMI indicates body mass index; BP, blood pressure; and HOMA, homeostasis model assessment. *Low and high levels of baseline BMI were defined as BMI below and above 25, respectively, and low and high levels of baseline HOMA were defined as <45th and >55th percentiles, respectively. †P values for difference in continuous variables among 4 groups were adjusted for age, race, and sex. ‡P values for difference in continuous variables between groups III and IV were adjusted for age, race, and sex. §Individuals who took medications were excluded. WC and HOMA as shown in Table S1 in the online-only Data Supplement. The prevalence of incident hypertension at follow-up in group IV was significantly higher than in group III (32.7% versus 21.1%, P=0.004), which was similar to the prevalence in Table 2 . The association parameters using groups III and IV defined by WC in Table S2 were close to those as shown in Table 3 . Furthermore, the interaction effects of baseline WC with HOMA on hypertension and BP levels at follow-up (data not shown) were substantially similar to the interaction effects as shown in Figures 2 and 3 .
Discussion
It is almost indisputable that adiposity is one of the most important risk factors related to the development of hypertension.
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Although adiposity and insulin resistance are highly correlated, the causal role of insulin resistance in the development of hypertension continues to be debated. 21, [23] [24] [25] [26] The Bogalusa Heart Study has reported that childhood BMI and insulin predict adulthood levels of BP, with BMI being more predictive than insulin. [30] [31] [32] However, previous data did not examine whether insulin resistance modifies the relationship between adiposity and hypertension. In this prospective cohort study, we confirmed the hypothesis that individuals with insulin-resistant adiposity were more likely to develop hypertension than those with insulin-sensitive adiposity. This study provides strong evidence that effect of adiposity on the development of hypertension is modified by insulin resistance in middle-aged adults.
A subset of obese individuals who are characterized by higher insulin sensitivity are often described as metabolically healthy obese, and insulin-sensitive adiposity may protect individuals to some extent against obesity-related metabolic complications. 7, 8 Genelhu et al 9 have shown that the risk of developing hypertension, type 2 diabetes mellitus, and cardiovascular disease is accentuated in obese individuals with insulin resistance in a population of Brazilians. A cross-sectional study showed that insulin-sensitive obese children had significantly lower levels of BP compared with their insulin-resistant peers. 10 Ikeda et al 33 reported a distinct relation between improvement of insulin sensitivity and a decrease in BP after weight loss in obese hypertensive subjects. Furthermore, Lim et al 34 found that the elevation of BP in high-fat-fed rabbits is moderately mediated by central actions of insulin. However, some previous studies did not support the notion that overweight/obesity with insulin sensitivity are benign conditions. 35 In this study, we found that individuals with insulin-resistant obesity at baseline were 1.9 times more likely to have hypertension 16 years later on average than those with insulin-sensitive obesity, and the strength of the association significantly increased across increasing baseline HOMA levels in terms of obesity defined by both BMI and WC. The observations from this study expand previous findings by demonstrating that the relationship between adiposity and hypertension is modified by insulin resistance. The modification effect of insulin resistance on the adiposity-hypertension association noted in this study is to some extent in agreement with observations from the Swedish Obese Subjects (SOS) trial-a prospective controlled intervention study of bariatric surgery. The findings of the SOS study have clearly demonstrated that the beneficial effect of the surgical treatment on future outcomes, including overall mortality, myocardial infarction, stroke, diabetes mellitus, and cancer, is associated with improvement in baseline insulin resistance but not with baseline BMI. 36 The effect of bariatric surgery on diabetes mellitus is influenced by the presence or the absence of impaired fasting glucose but not by BMI. 37 In this study, it is found that blacks had higher HOMA than whites in females at both baseline and follow-up. However, the strength of the association of baseline BMI and WC with follow-up hypertension across levels of baseline HOMA did not differ between races. To the best of our knowledge, this is the first longitudinal cohort study to examine the interplay of adiposity and insulin resistance on the development of hypertension in the black and white population. Our data indicated that insulin resistance amplified the association between adiposity and hypertension equally in both races. These observations in black-white race groups need to be confirmed and replicated in other population studies.
There are several putative mechanisms linking adiposity and insulin resistance to hypertension. Obesity is associated with dietary excess or some diminished capacity for thermogenesis (a low metabolic rate) and results in insulin resistance. Our previous studies have found temporal nature of the relation from obesity to insulin resistance during childhood and adulthood. 38 Obesity and insulin resistance may jointly increase sympathetic nervous system activity, which is subsequently involved in the pathogenesis of obesity-related hypertension. 39 The significant, positive correlations of baseline heart rate, a marker of sympathetic nervous system tone, with insulin and BP at both baseline and follow-up found in this study provided further evidence to support this concept. Second, insulin may enhance sodium retention by directly increasing sodium reabsorption in renal tubules and indirectly through the activation of the renin-angiotensin system and sympathetic nervous system. 40 Studies have suggested that insulin resistance activates the renin-angiotensin system by increasing expression of angiotensinogen, angiotensin I and II receptors, which may contribute to the development of hypertension in patients with insulin resistance. 41 It has been recently discovered that adipocytes produce aldosterone in response to angiotensin II. 42 There is also evidence that insulin resistance activates the sympathetic nervous system, increases kidney sodium reabsorption, heart cardiac output, and vasoconstriction and finally leads to elevated BP levels. 43 Third, obese individuals with insulin resistance might have additional predisposing factors when compared with insulinsensitive obese individuals, for example higher lipid deposition in intramyocellular and visceral compartments and lower adiponectin levels. 44, 45 Under such conditions, insulin resistance may amplify the adverse effect of obesity on the development of hypertension.
This community-based, longitudinal cohort provided a unique opportunity to test the effect of insulin resistance on the obesity-hypertension association in adulthood. This study has some limitations. First, it seems broad to categorize baseline insulin resistance as top 45th percentile of baseline HOMA. The relatively small sample size with limited statistical power was the primary consideration for the selection of the cut-off value. In sensitivity analyses using a cut-off value of top 25th percentile of HOMA, ORs still remained significant. Second, the follow-up period of the study subjects varied from 5.0 to 31.2 years. The wide range of follow-up time might have an influence on the obesity/insulin resistance-hypertension association. For this reason, the number of follow-up years was included in all logistic models for adjustment in the current analysis. Moreover, we conducted additional association analyses by tertile groups of follow-up year and did not find a significant difference in ORs among 3 subgroups.
Perspectives
This study demonstrates that insulin-resistant obesity is associated with increased risk of hypertension when compared with insulin-sensitive adiposity, and the obesity-hypertension association is strengthened by the presence of insulin resistance. These results support the notion that that insulin resistance has a synergistic effect on the obesity-hypertension association in middle-aged adults. The findings underscore the importance of controlling both obesity and insulin resistance to prevent the future development of hypertension. 
